Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3201/1107.050219 http://scihub22266oqcxt.onion/10.3201/1107.050219 16022774!3371787!16022774     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=16022774&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Emerg+Infect+Dis 2005 ; 11 (7): 1016-20 Nephropedia Template TP {{tp|p=16022774|t=2005. SARS vaccine development |pdf=|usr=}}{{16022774}} gab.com Text SARS vaccine development JO: Emerg Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=16022774 #FOAvip Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines. Twit Text FOAVip SARS vaccine development ????Emerg Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=16022774 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=16022774 #FOAvip English Wikipedia <ref>{{Cite pmid|16022774}}</ref> SARS vaccine development #MMPMID16022774 Jiang S; He Y; Liu S Emerg Infect Dis 2005[Jul]; 11 (7): 1016-20 PMID16022774show ga Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines. |*Viral Vaccines[MESH] |Epitopes[MESH] |Humans[MESH] |Membrane Glycoproteins/immunology[MESH] |Severe Acute Respiratory Syndrome/*prevention & control[MESH] |Severe acute respiratory syndrome-related coronavirus/*immunology[MESH] |Spike Glycoprotein, Coronavirus[MESH] |Vaccines, Inactivated[MESH]SARS vaccine development (epmc).pdf DeepDyve Pubget Overpricing